Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Element Biosciences in the transaction. Element Biosciences Inc., developer of pioneering technologies to empower science, announced it raised...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Contineum Therapeutics in the offering, and Sidley Austin represented the underwriters. Contineum Therapeutics, a clinical stage biopharmaceutical company,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian acted as counsel to Tarsus Pharmaceuticals in the offering, Hogan Lovells acted as regulatory counsel while Knobbe Martens Olson...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Natera, and Davis Polk & Wardwell advised the representatives of the several underwriters on the offering. Natera, Inc....
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised sales agents Goldman Sachs & Co. LLC and SVB Securities on the deal. Goldman Sachs & Co. LLC and SVB Securities acted as sales agents in...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Brightseed on the deal. Brightseed, a San Francisco-based developer of plant nutrient technology, announced its $68 million Series B financing led by Temasek. Brightseed...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Raine Venture Partners on the deal. Raine Venture Partners acted as an investor in the $120 million Series...
You must be a Standard 1 Year member to access this content.
